Oral alpha-cyclodextrin reverses cholesterol-crystal-induced retinal pathology in a rodent model of type 2 diabetes (T2D)
Dyslipidemia is common in individuals with T2D and clinical studies show cholesterol and lipid management reduce diabetic retinopathy (DR) progression.